Indeed, vertical inhibition of the MAPK pathway—with BRAF inhibitors in combination with MEK and/or EGFR inhibitors—provides improved responses in BRAF mutant CRC compared to BRAF inhibitor alone [59, 60]. Here, EGFR is linked to colorectal carcinoma.